Endoscopic Multispectral Imaging for the Early Detection of Barrett’s Neoplasia
Overview
The overall objective of this pilot study is to determine whether multispectral imaging increases the diagnostic accuracy of the current standard of high-definition white-light endoscopy for the detection of Barrett's-associated neoplasia (high grade dysplasia or cancer). The investigators goal is to develop a multispectral endoscopic platform that can be used to survey a large surface area and, potentially, serve as a 'red flag' for microendoscopic imaging of small areas. The goal of this pilot study is to preliminarily determine the accuracy of these modalities during the endoscopic surveillance of Barrett's esophagus.
Full Title of Study: “Endoscopic Multispectral Imaging for the Early Detection of Barrett’s Neoplasia”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Screening
- Masking: None (Open Label)
- Study Primary Completion Date: December 2015
Interventions
- Drug: proflavine
- 2-6 ml of 0.01% proflavine
Arms, Groups and Cohorts
- Experimental: treatment
- fluorescent imaging with proflavine
Clinical Trial Outcome Measures
Primary Measures
- to determine whether tissue is neoplastic or non-neoplastic
- Time Frame: 1 day
Participating in This Clinical Trial
Inclusion Criteria
- 18 years or older – known or suspected barrett's esophagus with intraepithelial neoplasia(HGD/cancer) Exclusion Criteria:
-
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Anandasabapathy, Sharmila, M.D.
- Collaborator
- William Marsh Rice University
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.